生物类似物胰岛素概念。 - Suppr

Suppr

超能文献

Biosimilar insulin concepts.

作者信息

Bloomgarden Zachary T

机构信息

Icahn School of Medicine, Mount Sinai, New York, NY, USA.

出版信息

J Diabetes. 2022 Apr;14(4):231-235. doi: 10.1111/1753-0407.13267. Epub 2022 Mar 28.

DOI:10.1111/1753-0407.13267

PMID:35347893

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9060021/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eee0/9060021/1bfb388b91df/JDB-14-231-g002.jpg

相似文献

Biosimilar insulin concepts.

J Diabetes. 2022 Apr;14(4):231-235. doi: 10.1111/1753-0407.13267. Epub 2022 Mar 28.

J Diabetes. 2015 Mar;7(2):153-4. doi: 10.1111/1753-0407.12243. Epub 2015 Jan 13.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2019 Feb;21(S1):S57-S78. doi: 10.1089/dia.2019.2505.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2016 Feb;18 Suppl 1:S43-55. doi: 10.1089/dia.2016.2505.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2018 Feb;20(S1):S55-S70. doi: 10.1089/dia.2018.2505.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2023 Feb;25(S1):S44-S69. doi: 10.1089/dia.2023.2504.

The impact of biosimilar insulins on the diabetes landscape.

J Manag Care Spec Pharm. 2022 Jan;28(1):91-98. doi: 10.18553/jmcp.2021.21253. Epub 2021 Nov 2.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2021 Jun;23(S2):S46-S68. doi: 10.1089/dia.2021.2504.

Administration of Biosimilar Insulin Analogs: Role of Devices.

Diabetes Technol Ther. 2017 Feb;19(2):79-84. doi: 10.1089/dia.2016.0263.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2020 Feb;22(S1):S32-S46. doi: 10.1089/dia.2020.2503.

本文引用的文献

The insulin market reaches 100.

Diabetologia. 2022 Jun;65(6):931-935. doi: 10.1007/s00125-022-05680-y. Epub 2022 Mar 11.

Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis.

BMC Endocr Disord. 2022 Feb 5;22(1):35. doi: 10.1186/s12902-022-00944-5.

The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.

J Diabetes Sci Technol. 2023 Mar;17(2):490-494. doi: 10.1177/19322968211067511. Epub 2021 Dec 31.

Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials.

Endocrine. 2021 Dec;74(3):508-517. doi: 10.1007/s12020-021-02889-6. Epub 2021 Oct 2.

Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes.

J Pharm Pract. 2021 May 18:8971900211017867. doi: 10.1177/08971900211017867.

Day-to-day variability of insulin requirements in the inpatient setting: Observations during fully closed-loop insulin delivery.

Diabetes Obes Metab. 2021 Aug;23(8):1978-1982. doi: 10.1111/dom.14396. Epub 2021 May 4.

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes.

Diabetes Metab Syndr Obes. 2021 Jan 12;14:107-116. doi: 10.2147/DMSO.S279385. eCollection 2021.

Efficacy, Safety, and Immunogenicity of Insulin Aspart Biosimilar SAR341402 Compared with Originator Insulin Aspart in Adults with Diabetes (GEMELLI 1): A Subgroup Analysis by Prior Type of Mealtime Insulin.

Diabetes Ther. 2021 Feb;12(2):557-568. doi: 10.1007/s13300-020-00992-x. Epub 2021 Jan 11.

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.

Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis.

Health Promot Perspect. 2020 Mar 30;10(2):98-115. doi: 10.34172/hpp.2020.18. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Biosimilar insulin concepts.

J Diabetes. 2022 Apr;14(4):231-235. doi: 10.1111/1753-0407.13267. Epub 2022 Mar 28.

J Diabetes. 2015 Mar;7(2):153-4. doi: 10.1111/1753-0407.12243. Epub 2015 Jan 13.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2019 Feb;21(S1):S57-S78. doi: 10.1089/dia.2019.2505.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2016 Feb;18 Suppl 1:S43-55. doi: 10.1089/dia.2016.2505.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2018 Feb;20(S1):S55-S70. doi: 10.1089/dia.2018.2505.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2023 Feb;25(S1):S44-S69. doi: 10.1089/dia.2023.2504.

The impact of biosimilar insulins on the diabetes landscape.

J Manag Care Spec Pharm. 2022 Jan;28(1):91-98. doi: 10.18553/jmcp.2021.21253. Epub 2021 Nov 2.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2021 Jun;23(S2):S46-S68. doi: 10.1089/dia.2021.2504.

Administration of Biosimilar Insulin Analogs: Role of Devices.

Diabetes Technol Ther. 2017 Feb;19(2):79-84. doi: 10.1089/dia.2016.0263.

New Insulins, Biosimilars, and Insulin Therapy.

Diabetes Technol Ther. 2020 Feb;22(S1):S32-S46. doi: 10.1089/dia.2020.2503.

本文引用的文献

The insulin market reaches 100.

Diabetologia. 2022 Jun;65(6):931-935. doi: 10.1007/s00125-022-05680-y. Epub 2022 Mar 11.

Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis.

BMC Endocr Disord. 2022 Feb 5;22(1):35. doi: 10.1186/s12902-022-00944-5.

The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.

J Diabetes Sci Technol. 2023 Mar;17(2):490-494. doi: 10.1177/19322968211067511. Epub 2021 Dec 31.

Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials.

Endocrine. 2021 Dec;74(3):508-517. doi: 10.1007/s12020-021-02889-6. Epub 2021 Oct 2.

Glycemic Variability With Insulin Glargine Versus Detemir in Hospitalized Patients With Diabetes.

J Pharm Pract. 2021 May 18:8971900211017867. doi: 10.1177/08971900211017867.

Day-to-day variability of insulin requirements in the inpatient setting: Observations during fully closed-loop insulin delivery.

Diabetes Obes Metab. 2021 Aug;23(8):1978-1982. doi: 10.1111/dom.14396. Epub 2021 May 4.

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes.

Diabetes Metab Syndr Obes. 2021 Jan 12;14:107-116. doi: 10.2147/DMSO.S279385. eCollection 2021.

Diabetes Ther. 2021 Feb;12(2):557-568. doi: 10.1007/s13300-020-00992-x. Epub 2021 Jan 11.

(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.

Cochrane Database Syst Rev. 2020 Nov 9;11(11):CD005613. doi: 10.1002/14651858.CD005613.pub4.

Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis.

Health Promot Perspect. 2020 Mar 30;10(2):98-115. doi: 10.34172/hpp.2020.18. eCollection 2020.